Quantitative phosphoproteomics of chronic sunitinib treated renal cell carcinoma 786-O cells with GPR30 agonist G-1

In this project, we generated chronic sunitinib-treated 786-O cell, a renal cell carcinoma cell line. In order to investigate the possible effect of GPR30 agonist, G-1, on the growth-inhibtion related signaling pathways, we treated either parental both parental and chronic sunitinib-treated 786-O cells were treated either by vehicle-only (i.e. 0.1% DMSO) or 2 μM G-1 for 48 h. Therefore, there were three groups for comparison, including G-1 treatment (G-1 vs. parental), chronic sunitinib-treatment (SunR vs. parental), and G-1 treatment in SunR cells (SunR&G-1 vs. parental).

本研究中，我们成功构建了经长期舒尼替尼（sunitinib）处理的786-O细胞系，该细胞系为肾细胞癌细胞系。为探究GPR30激动剂（GPR30 agonist）G-1对生长抑制相关信号通路的潜在调控效应，我们分别对亲本786-O细胞与长期舒尼替尼处理的786-O细胞施加两种干预方式：仅添加溶剂对照（即0.1%二甲基亚砜（DMSO）），或2 μM G-1，干预时长为48小时。本实验共设置三组用于对照比较：G-1处理组（G-1 vs 亲本细胞）、长期舒尼替尼处理组（SunR vs 亲本细胞），以及SunR细胞的G-1处理组（SunR&G-1 vs 亲本细胞）。